110 EAST 59TH STREET, NEW YORK, NY
Earnings Release
Positive Phase 3 Results for Daraxonrasib in Metastatic PDAC Announced
Annual Report to Security Holders
Reports Q4 and Full Year 2025 Results
Executive Transition - George W. Lloyd to Step Down as Chief Legal Officer
FDA Approves MYQORZO for Treatment of Obstructive Hypertrophic Cardiomyopathy
Reports Third Quarter 2025 Results
News, Underwriting Agreement, Securities Holder Rights or Indentures, Legal Opinion
Q1
FY 2024
Q3
Q2
FY 2023
Prospectus Filed Pursuant to Rule 424(b)(2)
Registration Statement for Securities to be Offered to Employees
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Definitive Merger Proxy Statement
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
13F Holdings Report - Notice
Free Writing Prospectus
Automatic Shelf Registration Statement